We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+26.9%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$1.05B
AUM Growth
+$91.8M
Cap. Flow
-$24.1M
Cap. Flow %
-2.3%
Top 10 Hldgs %
32.3%
Holding
111
New
20
Increased
23
Reduced
56
Closed
11

Top Buys

Rank Stock Value
1
MASI
Masimo
MASI
+$28.6M
2
DXCM icon
DexCom
DXCM
+$26.9M
3
EYPT icon
EyePoint Inc
EYPT
+$15.4M
4
WAT icon
Waters Corp
WAT
+$15.4M
5
MTD icon
Mettler-Toledo International
MTD
+$15.3M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$17.7M
2
BIIB icon
Biogen
BIIB
+$15.5M
3
DHR icon
Danaher
DHR
+$11.4M
4
CSTL icon
Castle Biosciences
CSTL
+$10.5M
5
VRDN icon
Viridian Therapeutics
VRDN
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZBH icon
26
Zimmer Biomet
ZBH
$18.7B
$13.6M 1.29%
151,049
-100,371
-40% -$9.52M
DHR icon
27
Danaher
DHR
$145B
$13.5M 1.28%
58,889
-51,652
-47% -$11.4M
XERS icon
28
Xeris Biopharma Holdings
XERS
$1.55B
$13.3M 1.26%
1,691,585
-100,089
-6% -$788K
EW icon
29
Edwards Lifesciences
EW
$53.6B
$12.9M 1.23%
150,985
-4,781
-3% -$392K
PTCT icon
30
PTC Therapeutics
PTCT
$6.06B
$12.2M 1.16%
160,179
-42,184
-21% -$3.07M
WAY
31
Waystar Holding Corp
WAY
$4.71B
$12.1M 1.15%
369,023
+62,996
+21% +$2.24M
SNDX icon
32
Syndax Pharmaceuticals
SNDX
$1.77B
$12.1M 1.15%
574,023
-272,876
-32% -$4.76M
THC icon
33
Tenet Healthcare
THC
$21.5B
$12M 1.14%
60,514
-13,816
-19% -$2.79M
NUVL
34
DELISTED
Nuvalent
NUVL
$11.9M 1.14%
118,712
-1,478
-1% -$146K
ANIP icon
35
ANI Pharmaceuticals
ANIP
$1.73B
$11.4M 1.09%
+145,000
New +$12.6M
EWTX icon
36
Edgewise Therapeutics
EWTX
$4.73B
$10.6M 1.01%
427,690
-122,483
-22% -$2.46M
UNH icon
37
UnitedHealth
UNH
$364B
$10.5M 1%
+31,875
New +$10.8M
COO icon
38
Cooper Companies
COO
$15B
$10.3M 0.98%
125,335
-51,188
-29% -$3.83M
AORT icon
39
Artivion
AORT
$1.4B
$9.97M 0.95%
218,669
-2,375
-1% -$106K
APGE icon
40
Apogee Therapeutics
APGE
$10.2B
$9.82M 0.93%
130,069
+24,238
+23% +$1.53M
MAZE
41
Maze Therapeutics
MAZE
$1.52B
$8.67M 0.83%
209,266
+9,266
+5% +$318K
ASMB icon
42
Assembly Biosciences
ASMB
$536M
$8.48M 0.81%
249,357
-1,624
-0.6% -$52.3K
ACLX
43
DELISTED
Arcellx
ACLX
$8.35M 0.8%
128,111
-21,737
-15% -$1.73M
AXGN icon
44
Axogen
AXGN
$2.67B
$8.19M 0.78%
250,318
-251,514
-50% -$6.19M
IQV icon
45
IQVIA
IQV
$39.8B
$7.94M 0.76%
35,230
+5,230
+17% +$1.14M
SIBN icon
46
SI-BONE Inc
SIBN
$852M
$7.38M 0.7%
374,382
-4,201
-1% -$73K
DOCS icon
47
Doximity
DOCS
$4.45B
$7.19M 0.68%
162,276
-16,694
-9% -$937K
BCRX icon
48
BioCryst Pharmaceuticals
BCRX
$2.71B
$7.02M 0.67%
900,057
-112,607
-11% -$814K
XENE icon
49
Xenon Pharmaceuticals
XENE
$6.31B
$6.91M 0.66%
154,184
-21,953
-12% -$922K
OPRX icon
50
OptimizeRx
OPRX
$132M
$6.6M 0.63%
538,649
+29,038
+6% +$474K
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Parkman Healthcare Partners held 111 positions worth $1.05B, up 9.6% from $959M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q4 2025 filing shows 20 new, 23 increased, 56 reduced and 11 closed positions. Its largest new stake was Masimo: 200,000 shares worth $26M. The largest sale was Alnylam Pharmaceuticals, an estimated $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • Parkman Healthcare Partners's largest Q4 2025 buy was Masimo: 200,000 shares worth $26M.
  • Parkman Healthcare Partners added most to DexCom in Q4 2025, an estimated $26.9M increase.
  • Parkman Healthcare Partners's biggest Q4 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $17.7M.
  • Parkman Healthcare Partners fully exited United Therapeutics in Q4 2025, selling an estimated $9.22M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $1.05B portfolio in Q4 2025.
  • Parkman Healthcare Partners opened 20 new positions and closed 11 in Q4 2025.
  • Parkman Healthcare Partners's portfolio value rose 9.6% quarter-over-quarter to $1.05B.

Based on Parkman Healthcare Partners's 13F filing for Q4 2025, filed 17 Feb 2026.